Results 221 to 230 of about 1,626,235 (296)

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Aprepitant-loaded solid lipid nanoparticles: a novel approach to enhance oral bioavailability. [PDF]

Beilstein J Nanotechnol
Hussain M, Farooq M, Saeed MA, Ijaz M, Adnan S, Masood Z, Waqas M, Ishaq W, Ameer N.   +8 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Transporter‐Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray

Clinical Pharmacology &Therapeutics, EarlyView.
Zavegepant nasal spray, a calcitonin gene‐related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na+/taurocholate cotransporting polypeptide (NTCP), P‐glycoprotein (P‐gp), and cytochrome P450 3A4 (CYP3A4).
Alice Ke, Ernesto Callegari, Manthena V.S. Varma, Mayur K Ladumor, Chieko Muto, Richard J. Bertz, Hannah M. Jones, Vaishali Sahasrabudhe, Jing Liu   +8 more
wiley   +1 more source

Enhancement of oral bioavailability of risedronate through xyloglucan rafts. [PDF]

J Pharm Pharm Sci
Namazi NI, Bafail R, Alanezi AA, Almuqati AF, Alshammari MS, Alghamdi MA.   +5 more
europepmc   +1 more source

The Governance Gap: Democratizing Drug Development Through Decision Architecture

Clinical Pharmacology &Therapeutics, EarlyView.
Drug development is most exposed to governance failure where it can least afford it, in global health. The field has more predictive power than at any point in its history and roughly the same failure rate it had a decade ago. We argue that this paradox persists because the field has invested heavily in prediction science while neglecting decision ...
Craig R. Rayner, Nancy E. Martin, Danielle Smith, Eliza Kruger, Carl M.J. Kirkpatrick, Goonaseelan (Colin) Pillai, Katy Moore, Darrell Nix, Cristina Donini, Jakob P. Cramer, Edmundo Muniz, Natalia Muniz, Ernst Bos, Douglas McNair, Shyam Bhaskaran, Mark Sullivan, Dan Hartman   +16 more
wiley   +1 more source

Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and <i>in vivo</i> pharmacokinetic evaluation. [PDF]

Nanoscale Adv
Sinha S, Ravi PR, Rashmi SR, Devaraju LK.   +3 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Development, Optimization, and Evaluation of Nano Self-Emulsifying Drug Delivery System Formulation Platform for Oral Bioavailability Enhancement of Sulfasalazine and Disulfiram in Lung Cancer Chemoprevention. [PDF]

Pharm Res
Desai P, Bang K, Chowdhury MRH, Wang ZK, Wang J, Prabhu S, Liang X, Kassie F.   +7 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic Acid. [PDF]

Antioxidants (Basel)
Alhyari D, Qinna NA, Sheldrake HM, Kantamneni S, Ghanem BY, Paluch KJ.   +5 more
europepmc   +1 more source